These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

493 related articles for article (PubMed ID: 23543703)

  • 1. NMDA hypofunction as a convergence point for progression and symptoms of schizophrenia.
    Snyder MA; Gao WJ
    Front Cell Neurosci; 2013; 7():31. PubMed ID: 23543703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NMDA receptor hypofunction for schizophrenia revisited: Perspectives from epigenetic mechanisms.
    Snyder MA; Gao WJ
    Schizophr Res; 2020 Mar; 217():60-70. PubMed ID: 30979669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The involvement of N-methyl-D-aspartate receptor (NMDAR) subunit NR1 in the pathophysiology of schizophrenia.
    Ju P; Cui D
    Acta Biochim Biophys Sin (Shanghai); 2016 Mar; 48(3):209-19. PubMed ID: 26837414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drugs Based on NMDAR Hypofunction Hypothesis in Schizophrenia.
    Wu Q; Huang J; Wu R
    Front Neurosci; 2021; 15():641047. PubMed ID: 33912003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interneuron NMDA Receptor Ablation Induces Hippocampus-Prefrontal Cortex Functional Hypoconnectivity after Adolescence in a Mouse Model of Schizophrenia.
    Alvarez RJ; Pafundo DE; Zold CL; Belforte JE
    J Neurosci; 2020 Apr; 40(16):3304-3317. PubMed ID: 32205341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. N-methyl-D-aspartate receptor hypofunction as a potential contributor to the progression and manifestation of many neurological disorders.
    Dong B; Yue Y; Dong H; Wang Y
    Front Mol Neurosci; 2023; 16():1174738. PubMed ID: 37396784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia?
    Kantrowitz JT; Javitt DC
    Brain Res Bull; 2010 Sep; 83(3-4):108-21. PubMed ID: 20417696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Can N-Methyl-D-Aspartate Receptor Hypofunction in Schizophrenia Be Localized to an Individual Cell Type?
    Bygrave AM; Kilonzo K; Kullmann DM; Bannerman DM; Kätzel D
    Front Psychiatry; 2019; 10():835. PubMed ID: 31824347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute NMDA receptor antagonism impairs working memory performance but not attention in rats-Implications for the NMDAr hypofunction theory of schizophrenia.
    Lee J; van den Buuse M; Nithianantharajah J; Jones NC
    Behav Neurosci; 2020 Aug; 134(4):323-331. PubMed ID: 32658524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The origin of NMDA receptor hypofunction in schizophrenia.
    Nakazawa K; Sapkota K
    Pharmacol Ther; 2020 Jan; 205():107426. PubMed ID: 31629007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subchronic pharmacological and chronic genetic NMDA receptor hypofunction differentially regulate the Akt signaling pathway and Arc expression in juvenile and adult mice.
    Takagi S; Balu DT; Coyle JT
    Schizophr Res; 2015 Mar; 162(1-3):216-21. PubMed ID: 25592804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Positive Allosteric Modulation as a Potential Therapeutic Strategy in Anti-NMDA Receptor Encephalitis.
    Warikoo N; Brunwasser SJ; Benz A; Shu HJ; Paul SM; Lewis M; Doherty J; Quirk M; Piccio L; Zorumski CF; Day GS; Mennerick S
    J Neurosci; 2018 Mar; 38(13):3218-3229. PubMed ID: 29476014
    [No Abstract]   [Full Text] [Related]  

  • 13. NMDAR Hypofunction Animal Models of Schizophrenia.
    Lee G; Zhou Y
    Front Mol Neurosci; 2019; 12():185. PubMed ID: 31417356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential and underlying mechanism of sarcosine (N-methylglycine) in N-methyl-D-aspartate (NMDA) receptor hypofunction models of schizophrenia.
    Pei JC; Hung WL; Lin BX; Shih MH; Lu LY; Luo DZ; Tai HC; Studer V; Min MY; Lai WS
    J Psychopharmacol; 2019 Oct; 33(10):1288-1302. PubMed ID: 31294644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The NMDA Receptor and Schizophrenia: From Pathophysiology to Treatment.
    Balu DT
    Adv Pharmacol; 2016; 76():351-82. PubMed ID: 27288082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An mGlu5-Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.
    Balu DT; Li Y; Takagi S; Presti KT; Ramikie TS; Rook JM; Jones CK; Lindsley CW; Conn PJ; Bolshakov VY; Coyle JT
    Neuropsychopharmacology; 2016 Jul; 41(8):2052-61. PubMed ID: 26741285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Directly and Indirectly Targeting the Glycine Modulatory Site to Modulate NMDA Receptor Function to Address Unmet Medical Needs of Patients With Schizophrenia.
    Pei JC; Luo DZ; Gau SS; Chang CY; Lai WS
    Front Psychiatry; 2021; 12():742058. PubMed ID: 34658976
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gestational methylazoxymethanol exposure leads to NMDAR dysfunction in hippocampus during early development and lasting deficits in learning.
    Snyder MA; Adelman AE; Gao WJ
    Neuropsychopharmacology; 2013 Jan; 38(2):328-40. PubMed ID: 22968815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Emerging Role of Altered d-Aspartate Metabolism in Schizophrenia: New Insights From Preclinical Models and Human Studies.
    Errico F; Nuzzo T; Carella M; Bertolino A; Usiello A
    Front Psychiatry; 2018; 9():559. PubMed ID: 30459655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cannabinoid receptor 1 associates with NMDA receptors to produce glutamatergic hypofunction: implications in psychosis and schizophrenia.
    Sánchez-Blázquez P; Rodríguez-Muñoz M; Garzón J
    Front Pharmacol; 2014 Jan; 4():169. PubMed ID: 24427139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.